Printer Friendly

CYTOGEN LICENSES RIGHTS TO TARGETING TECHNOLOGY

 PRINCETON, N.J., July 14 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) has licensed from the University of North Carolina exclusive worldwide rights to novel reagents and technology for identifying targeting peptides.
 These libraries are a source of specific binding molecules for targeting to cancer cells and are potentially useful in cancer diagnostic and therapeutic products.
 This process utilizes random peptide libraries expressing an extensive collection of long peptides. This approach permits the screening of a much more diverse family of compounds than was practical with previous methods and has already yielded several novel reagents.
 The libraries have been developed under sponsored research funded by Cytogen, and is already utilized in the company's Molecular Recognition Unit (MRU) program.
 President Thomas J. McKearn, M.D., Ph.D., stated, "This powerful and versatile technology perfectly complements the new proprietary linkers which are also a part of our MRU program. We are optimistic that these technologies are destined to result in new products important for diagnosing and treating disease."
 Cytogen is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. Cytogen uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 7/14/93
 /CONTACT: Mary Beals, director-Corporate Communications of Cytogen, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU: LIC

CC -- PH012 -- 1490 07/14/93 14:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:241
Previous Article:QUAKER STATE INTRODUCES A NEW PREMIUM TWO-CYCLE MOTOR OIL
Next Article:KFC LAUNCHES CHICKEN REVOLUTION; COLONEL'S ROTISSERIE GOLD BEGINS $100+ MILLION ROLLOUT
Topics:


Related Articles
CYTOGEN ACQUIRES RIGHTS TO UNILEVER CANCER PROGRAM
CYTOGEN AND CYTORAD ANNOUNCE EXPANDED AGREEMENT
CYTOGEN WELCOMES MICHAEL R. KURMAN AS DIRECTOR OF CANCER THERAPEUTICS, CLINICAL INVESTIGATIONS
CYTOGEN SIGNS AGREEMENT WITH THE IMPERIAL CANCER RESEARCH TECHNOLOGY AND CONFIRMS THIRD QUARTER RESULTS
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN STOCKHOLDERS APPROVE MERGER WITH CYTORAD
CYTOGEN Announces Issuance of PSMA Patent
Presentations at RSNA Suggest Combidex(R) Useful in Detecting the Spread of Cancer to Lymph Nodes; -- Studies Show Potential Role for Combidex in a...
Data from Phase III Study of Combidex(R) Published in Leading Radiology Journal; Study shows that investigational new drug is useful in detecting the...
Presentations at ISMRM Suggest Combidex(R) Useful in Detecting the Spread of Breast and Prostate Cancers to Lymph Nodes.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters